Literature DB >> 8348750

Clustering of neutrophil leucocytes in serum: possible role of C1q-containing immune complexes.

G Sturfelt1, H Jonsson, G Hellmer, A G Sjöholm.   

Abstract

Clustering activity for neutrophil granulocytes was generated in pooled normal human serum (NHS) by incubation of the serum with preformed IgG aggregates, but not in heat-treated NHS (56 degrees C, 30 min), indicating that the function was complement-dependent. Judging from results of experiments with complement-deficient sera, and serum depleted of C1q, factor D and properdin, recruitment of the complement system beyond C1 was not required for induction of the activity. Zymosan treatment of NHS resulted in some neutrophil clustering activity, but recombinant C5a had a limited effect. C1q added to heat-treated NHS in conjunction with performed IgG aggregates supported neutrophil clustering in a dose-dependent manner. The serum C1q inhibitor, a chondroitin 4-sulphate proteoglycan known to interact with the collagenous part of C1q, clearly reduced neutrophil clustering in heat-treated NHS supplemented with C1q and IgG aggregates. The C1q inhibitor also reduced the inherent neutrophil clustering activity of some sera from patients with systemic lupus erythematosus (SLE). Neutrophil clustering activity in SLE serum was earlier shown to be inversely related to the number of circulating neutrophils in vivo. Although the precise mechanisms remain unclear, we propose that C1q-containing immunoglobulin complexes mediate neutrophil clustering through C1q receptors, and that this might contribute to pathogenesis of immune complex diseases such as SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348750      PMCID: PMC1554845          DOI: 10.1111/j.1365-2249.1993.tb07972.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  New biological activity following intravascular activation of the complement cascade.

Authors:  C E McCall; L R De Chatelet; D Brown; P Lachmann
Journal:  Nature       Date:  1974-06-28       Impact factor: 49.962

3.  Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value.

Authors:  D E Hammerschmidt; L J Weaver; L D Hudson; P R Craddock; H S Jacob
Journal:  Lancet       Date:  1980-05-03       Impact factor: 79.321

4.  Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component.

Authors:  A J Tenner; N R Cooper
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

5.  Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.

Authors:  R G Medicus; A F Esser; H N Fernandez; H J Müller-Eberhard
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  C1q inhibitor (C1qINH): functional properties and possible relationship to a lymphocyte membrane-associated C1q precipitin.

Authors:  B Ghebrehiwet
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

7.  Purification and radiolabeling of human C1q.

Authors:  A J Tenner; P H Lesavre; N R Cooper
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

8.  Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells.

Authors:  A J Tenner; N R Cooper
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

9.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.

Authors:  D E Chenoweth; S W Cooper; T E Hugli; R W Stewart; E H Blackstone; J W Kirklin
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

10.  The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan.

Authors:  L Silvestri; J R Baker; L Rodén; R M Stroud
Journal:  J Biol Chem       Date:  1981-07-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.